Key Drivers
- Extremely high margin
- Large cash cushion
- Heavy R&D burn
AIAI Summary
Immunocore is now a hybrid commercial/pipeline investment—KIMMTRAK's $400M, very high‑margin revenue materially derisks the story but near‑term upside depends on sustained global commercial acceleration and multiple binary Phase‑3/readouts while material noncurrent debt and negative FCF mean investors should only add on clear commercial traction and preserved cash runway (sell if $30 support breaks or key trials fail).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Extremely high margin
- •Large cash cushion
- •Heavy R&D burn
IMCR pairs ultra-high gross margins and strong cash/investment liquidity with heavy R&D-driven operating losses, negative cash flow and elevated leverage that pressure its investment case.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Near $30 support
- •Lower recent highs
IMCR broke below its last-month SMA (~$31.99) and fell from $33.41 to $29.94, signaling short-term bearish momentum toward key $30 support (a break below would be notably negative) while $33.3–$33.7 is near-term resistance.
Drop from $33.41 (2026-03-09) to $29.94 (2026-03-20) indicates recent selling pressure
Sentiment & News
Key News Insights:
- •Strong 2025 sales
- •Moderated 2026 growth
- •Multiple 2H‑2026 readouts
Immunocore posted solid 2025 KIMMTRAK sales ($400M) and a healthy $864M cash balance but expects moderated 2026 revenue as it shifts toward a pipeline-driven year with multiple near‑term readouts.
The company's solid cash runway and concentrated upcoming data milestones make the stock increasingly event‑driven, raising upside if trial readouts impress but also heightening short‑term risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings